<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02970591</url>
  </required_header>
  <id_info>
    <org_study_id>Car-IBS 1511-01</org_study_id>
    <nct_id>NCT02970591</nct_id>
  </id_info>
  <brief_title>A Comparison of Three Different Treatment Options for Irritable Bowel Syndrome</brief_title>
  <acronym>CARIBS</acronym>
  <official_title>The Role of CARbohydrates in Irritable Bowel Syndrome (CARIBS): Protocol for a Randomized Controlled Trial Comparing Three Different Treatment Options</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sahlgrenska University Hospital, Sweden</source>
  <brief_summary>
    <textblock>
      Irritable Bowel Syndrome is a common disease to which there is no curable treatment. Diet is&#xD;
      considered to trigger symptoms associated with the clinical picture of IBS, and dietary&#xD;
      treatment is thus believed to relieve the symptoms of IBS. As the disease is very&#xD;
      heterogeneous in its manifestation, different treatment options might be indicated depending&#xD;
      on the predominant symptom. To investigate the response to different dietary treatment&#xD;
      options, a randomized controlled intervention trial will be carried out in adult patients&#xD;
      (&gt;18 y) with IBS according to Rome III criteria. The aim of this study is to compare the&#xD;
      response to two different dietary treatments or optimized medical treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a randomized controlled trial comparing three different treatments during four&#xD;
      weeks:&#xD;
&#xD;
        1. Combination of low FODMAP diet + traditional dietary advice (based on NICE&#xD;
           recommendations)&#xD;
&#xD;
             -  Eat at regular hours; 3 main meals and 3 snacks&#xD;
&#xD;
             -  Eat in peace, chew the food properly&#xD;
&#xD;
             -  Peel all fruits and vegetables&#xD;
&#xD;
             -  Limit intake of spicy and fatty foods, coffe, alcohol, avoid fizzy drinks and&#xD;
                chewing gum&#xD;
&#xD;
             -  Choose soluble rather than insoluble fibres&#xD;
&#xD;
             -  Avoid foods high in FODMAPs&#xD;
&#xD;
        2. Diet low in carbohydrates&#xD;
&#xD;
             -  10 E% carbohydrates, 25 E% protein, 65 E% fat&#xD;
&#xD;
             -  Larger amounts of fish, shellfish, meat, egg, dairy products (lactose free if&#xD;
                wanted) nuts, seeds, oil, vegetables&#xD;
&#xD;
             -  No sugary or starchy foods, e.g pasta, potatoes, bread, rice, most fruits&#xD;
&#xD;
             -  No specific consideration about FODMAP content&#xD;
&#xD;
        3. Optimized pharmacological tretament based on predominant symptom and previous experience&#xD;
           with pharmacological treatmment.&#xD;
&#xD;
      Pain/discomfort:&#xD;
&#xD;
        -  Pain: Amitriptyline 25 mg. Increase to 50 mg if needed&#xD;
&#xD;
        -  Episodic pain: Hyoscyamine 0,2mg 2x2; adjust dose if needed&#xD;
&#xD;
        -  Pain with diarrhea: Amitriptyline 25 mg. Increase dose if needed&#xD;
&#xD;
        -  Pain with constipation: Linaclotide 290 microgram 1x1&#xD;
&#xD;
      Constipation:&#xD;
&#xD;
        -  Bulking agent (Sterculia gum (Inolaxol) 1x1. Increase to 1x3 if needed&#xD;
&#xD;
        -  Osmotic laxative (Macrogol (Movicol) 1x1&#xD;
&#xD;
        -  Linaclotide 290 microgram 1x1 Diarrhea&#xD;
&#xD;
        -  Loperamide 1x2 . Adjust dose if needed&#xD;
&#xD;
        -  Cholestyramine 1x1. Increase ever 3-5 d as needed&#xD;
&#xD;
        -  Ondansetron 4mg 1x1. Increase to 1x2-3 if needed&#xD;
&#xD;
        -  Eluxadoline 100mg 1x2&#xD;
&#xD;
      Primary endpoint: IBS-SSS reduction &gt;50 points&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion (%) of patients who respond to treatment</measure>
    <time_frame>Baseline to 4 weeks</time_frame>
    <description>A responder is defined as having an IBS-SSS reduction &gt;50 points @ 4 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in symptom severity</measure>
    <time_frame>Baseline, 4 weeks, 3 and 6 months</time_frame>
    <description>Absolute and percentage change in IBS-SSS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determinants for GI symptoms by IBS-SSS</measure>
    <time_frame>Baseline, 4 weeks, 3 and 6 months</time_frame>
    <description>GI symptoms measured by IBS-SSS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determinants for GI symptoms by GSRS-IBS</measure>
    <time_frame>Baseline, 4 weeks, 3 and 6 months</time_frame>
    <description>GI symptoms measured by GSRS-IBS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictors of response to treatment</measure>
    <time_frame>Baseline to 4 weeks</time_frame>
    <description>Potential predictors include demographics, questionnaire data, microbiota, metabolites, immunology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to allocated intervention</measure>
    <time_frame>Baseline, 4 weeks, 3 and 6 months</time_frame>
    <description>Including compliance to dietary intervention during 4 weeks, and long-term adherence during follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in microbiota content</measure>
    <time_frame>Baseline, 4 weeks, 6 months</time_frame>
    <description>Fecal microbiota analysis using 16S technique</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in extra-intestinal symptoms and quality of life</measure>
    <time_frame>Baseline, 4 weeks, 3 and 6 months</time_frame>
    <description>As assessed by IBS specific questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in metabolic profile</measure>
    <time_frame>Baseline, 4 weeks, 6 months</time_frame>
    <description>Metabolomics in serum and urine samples</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Qualitative assessment</measure>
    <time_frame>Approx. at 3 months follow-up</time_frame>
    <description>Patient's subjective experiences related to the dietary intervention described by qualitative methods.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Diet B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low carbohydrate diet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medical treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Optimized Medical treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diet A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Traditional dietary advice and low FODMAP content</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Traditional dietary advice and low FODMAP content</intervention_name>
    <description>Traditional dietary advice according to the Brittish Dietetic Association including reducing the intake of fermentable carbohydrates.</description>
    <arm_group_label>Diet A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Low carbohydrate diet</intervention_name>
    <description>Diet that contains a maximum of 10 energy percent of carbohydrates, 25 energy % proteins and 65 energy % fat.</description>
    <arm_group_label>Diet B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Optimized Medical treatment</intervention_name>
    <description>Standard consultation by physician and if needed patients will receive medical treatment based on the most prominent symptom. Constipation: osmotic laxatives, linaclotide. Diarrhea: loperamid, bile acid binders. Pain: anti depressent, antispasmodics, linaclotide.</description>
    <arm_group_label>Medical treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  IBS according to ROME III criteria, BMI 18-35, ability to communicate in Swedish,&#xD;
             Gothenburg region resident&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Heart, liver, neurologic or psychiatric disease or illness&#xD;
&#xD;
          -  Serious gastrointestinal diseases&#xD;
&#xD;
          -  Celiac disease&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  Other conditions or surgery that affects the gastrointestinal function&#xD;
&#xD;
          -  Hyperlipidemia&#xD;
&#xD;
          -  Food allergy or intolerance other than lactose&#xD;
&#xD;
          -  Adherence to a specific diet&#xD;
&#xD;
          -  Being pregnant or breastfeeding&#xD;
&#xD;
          -  Previously been treated with any of the intervention arms, including having tested all&#xD;
             of the pharmacological treatment options of relevance for the symptom profile of the&#xD;
             patient&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Magnus Simren</name>
      <address>
        <city>Gothenburg</city>
        <state>Non-US/Non-Canadian</state>
        <zip>44331</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magnus Simrén, MD, PhD</last_name>
      <phone>+46313421000</phone>
      <email>magnus.simren@medicine.gu.se</email>
    </contact>
    <investigator>
      <last_name>Magnus Simrén, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 18, 2016</study_first_submitted>
  <study_first_submitted_qc>November 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2016</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sahlgrenska University Hospital, Sweden</investigator_affiliation>
    <investigator_full_name>Magnus Simrén</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>FODMAPS</keyword>
  <keyword>carbohydrates</keyword>
  <keyword>metabolomics</keyword>
  <keyword>microbiota</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

